The stock market rally finally suffered substantial losses Thursday as the 10-year Treasury yields continue to rise. So, do we find ourselves staring down the barrel of a broad stock market retreat or a sector rotation? | |  | We've been waiting on some actual good news this week, and with only half an hour to spare before the closing bell, we finally got it...
The Food and Drug Administration came through with emergency authorization of the Pfizer vaccine for children ages 5 to 11. This will improve workforce participation rates — especially for women — which have not improved relative to pre-pandemic levels in many months.
And after a week where I took a loss on what I thought was a solid play, there is some positivity on the horizon. | | | | | | | | The last time the FDA made a call like this, one unsuspecting biotech ticker nearly tripled in eight days… And another cheap stock is poised to pop!
New Money Crew Head Trader Lance Ippolito bagged a 175% gain in a matter of eight days last time he spotted a trade just like this.
And it's not too late to get in!
So be sure to check out how this latest FDA decision could be worth upward of $100 million supercharging one $28 stock by the end of October… | | See the $100M Decision! | | |  | Bad GDP Numbers Overshadowed by Facebook's Meta Rebrand | October 29, 2021 | I sat in on my second earnings call this week, hoping to come to you with some good news. But instead… | | Continue Reading | | | | Disclaimer: The material in this document is for informational purposes based on our proprietary research. It is not an offering, specific recommendation, or a solicitation of an offer to buy or sell any securities mentioned or discussed herein. Any performance results discussed herein represent past performance, are not a guarantee of future performance, and are not indicative of any specific investment. Due to the timing of information presented, any investment performance reflected within this document may be adjusted after the publication and distribution of this material. There can be no assurance that the future performance of any specific investment, investment strategy, or product made reference to directly or indirectly in this communication will be profitable, be equal to any corresponding indicated historical performance levels or be suitable for your portfolio. Any investment results set forth in this document are not net of expenses and execution costs, nor do they account for other relevant trading or investment fees. Please visit wealthpress.com/terms for our full Terms and Conditions. | | | | |
This email was sent to edwardlorilla1986.paxforex@blogger.com by WealthPress LLC
No comments:
Post a Comment